Related references
Note: Only part of the references are listed.Clinical Course of Unilateral Moyamoya Disease
Ephraim W. Church et al.
NEUROSURGERY (2020)
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Taku Fujimura et al.
FRONTIERS IN MEDICINE (2019)
Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: Involvement of intrinsic immune reaction in its pathogenesis
Miki Fujimura et al.
BRAIN RESEARCH (2018)
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
Taku Fujimura et al.
FRONTIERS IN ONCOLOGY (2018)
Incidence and clinical features of disease progression in adult moyamoya disease
S Kuroda et al.
STROKE (2005)
Share Paper
